Planning for Fluid Biomarkers on a Larger Scale

ADC Director's Meeting Spring 2019

Rationale

Need to accelerate the development of blood-based biomarkers for ADRD

What are the obstacles?

- Uniformly collected, processed and stored specimens
- Availability of such specimens from diverse individuals with multimodal neuroimaging data and diagnostic heterogeneity
- Centralized process to request and receive samples

How to achieve this goal?

Pilot Study Broad Initiative

How to achieve this goal?

Pilot Study

Broad Initiative

Pilot Study NCRAD Administrative Supplement: ADRC Biomarker Initiative

18 ADCs

Blood collection from 3,000 subjects (all diagnoses)





Volume	Product
2x10 ml	Buffy coat (DNA) + Plasma aliquots
2x10 ml	PBMCs
1x10 ml	Serum aliquots
1x2.5 ml	RNA

- Samples listed in order of preference
- Not all Centers can collect 52.5 ml

Uniformly collected & processed blood samples



NCRAD Buffy coat (DNA), plasma, serum aliquots; Blood for RNA, PBMCs

What is the Advantage to ADRCs?

- ADRCs receive from NCRAD all materials for sample collection, processing and aliquoting
- ADRCs receive funding for sample collection
 - up to \$250/subject
- Reduced ADRC burden to store large numbers of samples
- Portion of each sample type sent to NCRAD reserved for contributing ADRC to request (*assuming full volume provided to NCRAD*)
 - Plasma: up to 3 ml
 - PBMC: one vial (3-4 million cells)
 - Serum: up to 1.5 ml
 - RNA: 2 ug

Pilot Study NCRAD Administrative Supplement: ADRC Biomarker Initiative

- May 2019 launch
- Memo already sent asking Centers to review consents and protocols to assess blood volumes
- While reviewing consents, please also review sharing language
- NCRAD website provides recommended consent language and guidance

Next Steps


Pilot Study Broad Initiative

What Do We Need?

- Strategy to have biomarker analyses run in all samples on a single platform in a single laboratory
 - ADRCs won't need to invest in a local biomarker analysis platform and take the risk that it will be obsolete in a few years
 - Examples of assays that could be run: A β , Tau, P-tau, NfL, etc.
- All efforts must cross talk with other large scale initiatives (ADNI, ATRI)
 - Provide cross validation or opportunities to coordinate effort

ADRC Fluid Biomarker Initiative: Overall Goals

- Support the nationwide network of ADRCs to include diverse participants in fluid biomarker research.
- Evaluate and select assays that can be optimized for scalable platforms to generate data for key biomarkers for samples banked from ADRC participants.
- Cross validate blood-based markers against contemporaneous imaging-derived (and eventually postmortem) ATN and other markers, and test whether or how associations are informed by social determinants of health (SDOH).
- Establish a biorepository available to the research community for future biomarker studies.



Diversity Core Rationale & Goals

CL: Lisa Barnes

Rationale: Most biomarker data within ADC comes from non-Latino Whites

- Of Centers that collect biomarkers on diverse populations, few consider important social determinants of health
- Social determinants include social conditions in which people are born, live, work, & age, that influence health outcomes
 - E.g., Socioeconomic status, neighborhood conditions, social disadvantage; psychosocial stress

Diversity Core Rationale & Goals

- Facilitate the sharing of successful models of engagement to increase availability of fluid biomarker data from underrepresented populations within the ADRCs
 - Work closely with Clinical Cores, Outreach & Education Cores, and the NIA
 - Provide pilot funding for innovative engagement programs
- Remote data collection from ADCs on social determinants of health
 - Create relevant metrics of social determinants
 - Centralized website where participants/informants can enter data from home
 - Link social determinants to fluid biomarker assays
 - Integrate social determinants into analyses to understand differences across race/ethnicity

ADRC Fluid Biomarker Initiative Workflow

Round robin for candidate fluid biomarkers



Validate in a well characterized (imaging) 'gold standard' cohort



Generalize across the ADRC participants

ADRD

1. ATN

2. Novel Biomarkers

How do ADCs benefit?

- Standardized collection protocol for which centers are paid
 - Blood, CSF, imaging (targeted subset)
- New data for the centers
 - Assay results
 - GWAS
 - Scan for a subset and processed results
 - Select routine labs (e.g., HbA1C)
 - Social determinants of health data
- Center has on reserve for 5 years at NCRAD a subset of their biospecimens, returned back to center at no cost
- Opportunities for training/education

Pilot Study Broad Initiative